CLOs on the Move

Vir Biotechnology

www.vir.bio

 
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world`s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vir.bio
  • 499 Illinois Suite 500
    San Francisco, CA USA 94158
  • Phone: 415.906.4324

Executives

Name Title Contact Details
Christen DiPetrillo
Director of Intellectual Property Profile
Irene Pleasure
Senior Vice President, General Counsel Profile
Stephen Leanos
Senior Director, Legal Profile

Similar Companies

Intarcia

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.

Strategic Partnerships

Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Demetrix

Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.

GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.